In this line, several clinical trial studies revealed that after intralesional injection of a commercial epidermal growth factor-based formulation (Heberprot-P) every other day in chronic and non-healing diabetic foot ulcers, most patients showed ulcer size reduction and signs of wound healing after 4–5 weeks of treatment [25,46]. This evidence concerns the gene EGF and diabetic foot.